uniQure (Nasdaq: QURE) has been a public company since 2014.

We thank our investors for their support as we advance our gene therapy pipeline toward commercialization.
Contact us at any time.

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders.

We are leveraging our modular and validated technology platform to rapidly advance a focused pipeline of gene therapies.

Stock Quote

Recent News

Recent Webcast

March 21, 2017
uniQure presents at Oppenheimer 27th
Annual Healthcare Conference 
Tuesday, March 21, 2017 
3.55 PM EDT/ 8.55 CET

Click here to view webcast

Upcoming Events

March 21-22, 2017
Oppenheimer's 27th Annual Healthcare Conference, New York City 
Presentation: Tuesday March 21st, 3.55 p.m. EDT

April 19-23, 2017
EASL - The International Liver Congress, Amsterdam, NL.

April 27, 2017
ARM Cell & Gene Therapy Investor Day, Boston, MA.
Presentation: Thursday April 27th, 2.15 p.m. EDT